Browsing by Author "Belluz, L.D.B."

Now showing 1 - 1 of 1

Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments
(Impact Journals, 2018) Alifrangis, C.; Carter, P.; Cereser, B.; Chandrasinghe, P.; Belluz, L.D.B.; Lim, E.; Moderau, N.; Poyia, F.; Tabassum, N.; Zhang, H.; Krell, J.; Stebbing, J.
In this study we utilized data on patient responses to guided treatments, and we evaluated their benefit for a non-small cell lung cancer cohort. The recommended therapies used were predicted using tumor molecular profiles that involved a range of biomarkers but primarily used immunohistochemistry markers. A dataset describing 91 lung non-small cell lung cancer patients was retrospectively split into two. The first group's drugs were consistent with a treatment plan whereby all drugs received agreed with their tumor's molecular profile. The second group each received one or more drug that was expected to lack benefit. We found that there was no significant difference in overall survival or mortality between the two groups. Patients whose treatments were predicted to be of benefit survived for an average of 402 days, compared to 382 days for those that did not (P = 0.7934). In the matched treatment group, 48% of patients were deceased by the time monitoring had finished compared to 53% in the unmatched group (P = 0.6094). The immunohistochemistry biomarker for the ERCC1 receptor was found to be a marker that could be used to predict future survival; ERCC1 loss was found to be predictive of poor survival.